Oral Ofloxacin: A Critical Review of the New Drug Application

Ofloxacin is a fluoroquinolone with activity against gram-positive and gram-negative aerobic and facultatively anaerobic bacteria, chlamydiae, and some related organisms, such as mycoplasmas or mycobacteria. It has been administered orally to 3,903 patients described in the New Drug Application (NDA...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 1992-02, Vol.14 (2), p.539-554
1. Verfasser: Sanders, Jr, W E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 554
container_issue 2
container_start_page 539
container_title Clinical infectious diseases
container_volume 14
creator Sanders, Jr, W E
description Ofloxacin is a fluoroquinolone with activity against gram-positive and gram-negative aerobic and facultatively anaerobic bacteria, chlamydiae, and some related organisms, such as mycoplasmas or mycobacteria. It has been administered orally to 3,903 patients described in the New Drug Application (NDA) submitted to the U.S. Food and Drug Administration. Although some components of the NDA lack scientific rigor or fail to mimic clinical practice, other components and the collective whole identify important potential advantages and limitations of the new drug. Ofloxacin was effective in the treatment of infections of the skin, soft tissues, urinary tract, and lower respiratory tract as well as in that of gonococcal and nongonococcal urethritis and prostatitis due to sensitive organisms. Adverse reactions were relatively infrequent, generally mild, and usually self-limiting. Symptoms involving the gastrointestinal tract and the central nervous system predominated. The emergence of resistance and superinfections were uncommon. Few adverse drug interactions were encountered, although antacids may diminish gastrointestinal absorption. In certain defined clinical situations, ofloxacin appears to be a useful addition to the therapeutic armamentarium.
doi_str_mv 10.1093/clinids/14.2.539
format Article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_16174777</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4456323</jstor_id><sourcerecordid>4456323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-ffc7607f330ad70bd45e4a2264ce2d93b057f7a046c361efcf52a014daaefad63</originalsourceid><addsrcrecordid>eNpFkD1PwzAYhC0EKlDYGUDKxJbWjr8SJIaqQIuoKOJDQiyW69jgkjbBTqD8e1ylKtN7ep-7Gw6AEwR7CGa4rwq7tLnvI9JLehRnO-AAUcxjRjO0GzSkaUxSnO6DQ-_nECKUQtoBHUQpSQk-AJdTJ4toaopyJZVdXkSDaOhsbVX4Pupvq3-i0kT1h47ug7xyzXs0qKoi8NqWyyOwZ2Th9fHmdsHLzfXzcBxPpqPb4WASK5ySOjZGcQa5wRjKnMNZTqgmMkkYUTrJMzyDlBsuIWEKM6SNMjSREJFcSm1kznAXnLe9lSu_Gu1rsbBe6aKQS102XiCGOOGcByNsjcqV3jttROXsQrpfgaBYLyY2iwlERCLCYiFytuluZgud_wfaiQI_bfnc16XbYkIow8kaxy22vtarLZbuUzCOORXj1zdxN6GjB_LEBcd_u2-Aag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16174777</pqid></control><display><type>article</type><title>Oral Ofloxacin: A Critical Review of the New Drug Application</title><source>MEDLINE</source><source>Oxford University Press Journals Digital Archive Legacy</source><source>Jstor Complete Legacy</source><creator>Sanders, Jr, W E</creator><creatorcontrib>Sanders, Jr, W E</creatorcontrib><description>Ofloxacin is a fluoroquinolone with activity against gram-positive and gram-negative aerobic and facultatively anaerobic bacteria, chlamydiae, and some related organisms, such as mycoplasmas or mycobacteria. It has been administered orally to 3,903 patients described in the New Drug Application (NDA) submitted to the U.S. Food and Drug Administration. Although some components of the NDA lack scientific rigor or fail to mimic clinical practice, other components and the collective whole identify important potential advantages and limitations of the new drug. Ofloxacin was effective in the treatment of infections of the skin, soft tissues, urinary tract, and lower respiratory tract as well as in that of gonococcal and nongonococcal urethritis and prostatitis due to sensitive organisms. Adverse reactions were relatively infrequent, generally mild, and usually self-limiting. Symptoms involving the gastrointestinal tract and the central nervous system predominated. The emergence of resistance and superinfections were uncommon. Few adverse drug interactions were encountered, although antacids may diminish gastrointestinal absorption. In certain defined clinical situations, ofloxacin appears to be a useful addition to the therapeutic armamentarium.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/clinids/14.2.539</identifier><identifier>PMID: 1554843</identifier><language>eng</language><publisher>United States: The University of Chicago Press</publisher><subject>Administration, Oral ; Adverse drug reactions ; Antibacterials ; Antimicrobials ; Bacterial Infections - drug therapy ; Chemotherapy ; Dosage ; Humans ; Infections ; Medical cures ; Ofloxacin - administration &amp; dosage ; Ofloxacin - adverse effects ; Ofloxacin - therapeutic use ; Quinolones ; Respiratory tract infections ; Review Articles ; Urinary tract infections</subject><ispartof>Clinical infectious diseases, 1992-02, Vol.14 (2), p.539-554</ispartof><rights>Copyright 1992 The University of Chicago</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-ffc7607f330ad70bd45e4a2264ce2d93b057f7a046c361efcf52a014daaefad63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4456323$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4456323$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,778,782,801,27907,27908,58000,58233</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1554843$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanders, Jr, W E</creatorcontrib><title>Oral Ofloxacin: A Critical Review of the New Drug Application</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>Ofloxacin is a fluoroquinolone with activity against gram-positive and gram-negative aerobic and facultatively anaerobic bacteria, chlamydiae, and some related organisms, such as mycoplasmas or mycobacteria. It has been administered orally to 3,903 patients described in the New Drug Application (NDA) submitted to the U.S. Food and Drug Administration. Although some components of the NDA lack scientific rigor or fail to mimic clinical practice, other components and the collective whole identify important potential advantages and limitations of the new drug. Ofloxacin was effective in the treatment of infections of the skin, soft tissues, urinary tract, and lower respiratory tract as well as in that of gonococcal and nongonococcal urethritis and prostatitis due to sensitive organisms. Adverse reactions were relatively infrequent, generally mild, and usually self-limiting. Symptoms involving the gastrointestinal tract and the central nervous system predominated. The emergence of resistance and superinfections were uncommon. Few adverse drug interactions were encountered, although antacids may diminish gastrointestinal absorption. In certain defined clinical situations, ofloxacin appears to be a useful addition to the therapeutic armamentarium.</description><subject>Administration, Oral</subject><subject>Adverse drug reactions</subject><subject>Antibacterials</subject><subject>Antimicrobials</subject><subject>Bacterial Infections - drug therapy</subject><subject>Chemotherapy</subject><subject>Dosage</subject><subject>Humans</subject><subject>Infections</subject><subject>Medical cures</subject><subject>Ofloxacin - administration &amp; dosage</subject><subject>Ofloxacin - adverse effects</subject><subject>Ofloxacin - therapeutic use</subject><subject>Quinolones</subject><subject>Respiratory tract infections</subject><subject>Review Articles</subject><subject>Urinary tract infections</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkD1PwzAYhC0EKlDYGUDKxJbWjr8SJIaqQIuoKOJDQiyW69jgkjbBTqD8e1ylKtN7ep-7Gw6AEwR7CGa4rwq7tLnvI9JLehRnO-AAUcxjRjO0GzSkaUxSnO6DQ-_nECKUQtoBHUQpSQk-AJdTJ4toaopyJZVdXkSDaOhsbVX4Pupvq3-i0kT1h47ug7xyzXs0qKoi8NqWyyOwZ2Th9fHmdsHLzfXzcBxPpqPb4WASK5ySOjZGcQa5wRjKnMNZTqgmMkkYUTrJMzyDlBsuIWEKM6SNMjSREJFcSm1kznAXnLe9lSu_Gu1rsbBe6aKQS102XiCGOOGcByNsjcqV3jttROXsQrpfgaBYLyY2iwlERCLCYiFytuluZgud_wfaiQI_bfnc16XbYkIow8kaxy22vtarLZbuUzCOORXj1zdxN6GjB_LEBcd_u2-Aag</recordid><startdate>19920201</startdate><enddate>19920201</enddate><creator>Sanders, Jr, W E</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>19920201</creationdate><title>Oral Ofloxacin: A Critical Review of the New Drug Application</title><author>Sanders, Jr, W E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-ffc7607f330ad70bd45e4a2264ce2d93b057f7a046c361efcf52a014daaefad63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Administration, Oral</topic><topic>Adverse drug reactions</topic><topic>Antibacterials</topic><topic>Antimicrobials</topic><topic>Bacterial Infections - drug therapy</topic><topic>Chemotherapy</topic><topic>Dosage</topic><topic>Humans</topic><topic>Infections</topic><topic>Medical cures</topic><topic>Ofloxacin - administration &amp; dosage</topic><topic>Ofloxacin - adverse effects</topic><topic>Ofloxacin - therapeutic use</topic><topic>Quinolones</topic><topic>Respiratory tract infections</topic><topic>Review Articles</topic><topic>Urinary tract infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanders, Jr, W E</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanders, Jr, W E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral Ofloxacin: A Critical Review of the New Drug Application</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>1992-02-01</date><risdate>1992</risdate><volume>14</volume><issue>2</issue><spage>539</spage><epage>554</epage><pages>539-554</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Ofloxacin is a fluoroquinolone with activity against gram-positive and gram-negative aerobic and facultatively anaerobic bacteria, chlamydiae, and some related organisms, such as mycoplasmas or mycobacteria. It has been administered orally to 3,903 patients described in the New Drug Application (NDA) submitted to the U.S. Food and Drug Administration. Although some components of the NDA lack scientific rigor or fail to mimic clinical practice, other components and the collective whole identify important potential advantages and limitations of the new drug. Ofloxacin was effective in the treatment of infections of the skin, soft tissues, urinary tract, and lower respiratory tract as well as in that of gonococcal and nongonococcal urethritis and prostatitis due to sensitive organisms. Adverse reactions were relatively infrequent, generally mild, and usually self-limiting. Symptoms involving the gastrointestinal tract and the central nervous system predominated. The emergence of resistance and superinfections were uncommon. Few adverse drug interactions were encountered, although antacids may diminish gastrointestinal absorption. In certain defined clinical situations, ofloxacin appears to be a useful addition to the therapeutic armamentarium.</abstract><cop>United States</cop><pub>The University of Chicago Press</pub><pmid>1554843</pmid><doi>10.1093/clinids/14.2.539</doi><tpages>16</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 1992-02, Vol.14 (2), p.539-554
issn 1058-4838
1537-6591
language eng
recordid cdi_proquest_miscellaneous_16174777
source MEDLINE; Oxford University Press Journals Digital Archive Legacy; Jstor Complete Legacy
subjects Administration, Oral
Adverse drug reactions
Antibacterials
Antimicrobials
Bacterial Infections - drug therapy
Chemotherapy
Dosage
Humans
Infections
Medical cures
Ofloxacin - administration & dosage
Ofloxacin - adverse effects
Ofloxacin - therapeutic use
Quinolones
Respiratory tract infections
Review Articles
Urinary tract infections
title Oral Ofloxacin: A Critical Review of the New Drug Application
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A15%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20Ofloxacin:%20A%20Critical%20Review%20of%20the%20New%20Drug%20Application&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Sanders,%20Jr,%20W%20E&rft.date=1992-02-01&rft.volume=14&rft.issue=2&rft.spage=539&rft.epage=554&rft.pages=539-554&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/clinids/14.2.539&rft_dat=%3Cjstor_proqu%3E4456323%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16174777&rft_id=info:pmid/1554843&rft_jstor_id=4456323&rfr_iscdi=true